Addor Capital

Addor Capital is a Nanjing-headquartered Chinese venture capital firm whose mandate centers on industrial upgrading, with biotechnology and medical manufacturing forming a substantial portion of its healthcare-relevant deployments. The firm operates within China’s policy-driven capital environment that emphasizes domestic biotech capability building, advanced medical device manufacturing, and life sciences industrialization. Its focus spans biotech and medical devices, with portfolio companies often aligned to national priorities around supply-chain localization and the maturation of Chinese pharmaceutical and device sectors.

The firm participates at Series A, Series B and Series C stages, with check sizes generally in the $5M to $25M range. Geographic activity is concentrated within China, with portfolio companies typically headquartered in Yangtze River Delta cities and other manufacturing hubs. Deal types include institutional equity rounds in growth-stage biotech and medical device businesses, often syndicated with other Chinese institutional investors and policy-aligned funds. Investments tend to favor companies with demonstrable revenue, clinical progress, or manufacturing capacity rather than pre-revenue scientific platforms.

For founders, Addor Capital offers institutional capital with deep linkages into the Chinese industrial and regulatory ecosystem. Companies appropriate for the firm typically have a China-centric commercial strategy, manufacturing localization plans, or a thesis aligned with domestic substitution of imported medical technology. The firm engages on commercial scaling, manufacturing partnerships, and navigation of the Chinese regulatory environment. Founders should expect standard institutional governance rights and a portfolio approach that emphasizes domestic market depth over international expansion. The firm is best suited to teams with native China presence or those pursuing Chinese market entry as a primary commercial objective.